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Abstract
Background: Epilepsy is a neurological disorder, characterized by recurrent unprovoked seizures which have a
high impact on the individual as well as on society as a whole. In addition to the economic burden, epilepsy
imposes a substantial burden on the patients and their surroundings. Patients with uncontrolled epilepsy depend
heavily on informal care and on health care professionals. About 30% of patients suffer from drug-resistant
epilepsy. The ketogenic diet can be a treatment of last resort, especially for children. The beneficial effect of the
ketogenic diet has been proven, but information is lacking about its cost-effectiveness. In the current study we will
evaluate the (cost-) effectiveness of the ketogenic diet in children and adolescents with intractable epilepsy.
Methods/Design: In a RCT we will compare the ketogenic diet with usual care. Embedded in this RCT will be a
trial-based and model-based economic evaluation, looking from a societal perspective at the cost-effectiveness and
cost-utility of the ketogenic diet versus usual care. Fifty children and adolescents (aged 1-18) with intractable
epilepsy will be screened for eligibility before randomization into the intervention or the usual care group. The
primary outcome measure is the proportion of children with a 50% or more reduction in seizure frequency.
Secondary outcomes include seizure severity, side effects/complaints, neurocognitive, socio-emotional functioning,
and quality of life. Costs and productivity losses will be assessed continuously by a prospective diary and a
retrospective questionnaire. Measurements will take place during consults at baseline, at 6 weeks and at 4 months
after the baseline period, and 3, 6, 9 and 12 months follow-up after the 4 months consult.
Discussion: The proposed research project will be the first study to provide data about the cost-effectiveness of
the ketogenic diet for children and adolescents with intractable epilepsy, in comparison with usual care. It is
anticipated that positive results in (cost-) effectiveness of the proposed intervention will contribute to the
improvement of treatment for epilepsy in children and adolescents and will lead to a smaller burden to society.
Trial registration: The study has been registered with the Netherlands Trial Registry (NTR2498).
Background
Epilepsy is a brain disorder characterized predominantly
by recurrent and unpredictable interruptions of normal
brain function. Seizures are transient occurrences of
signs and/or symptoms due to such abnormal excessive
or synchronous neuronal activities in the brain [1]. Dif-
ferent parts of the brain can be the site of such dis-
charges. The clinical manifestations of seizures will
therefore vary and depend on where in the brain the
disturbance first starts and how far it spreads. Transient
symptoms can occur, such as loss of awareness or con-
sciousness and disturbances of movement, sensation,
mood or mental function [1]. Furthermore, epilepsy is a
major cost-intensive and worldwide health problem [2].
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of the total burden of diseases in the world [3]. In Eur-
ope, about 3.4 million people suffer from epilepsy [4].
T h ea n n u a lt o t a lc o s t so fe p i l e p s yi nE u r o p ea r e€15.5
billion [5]. In the Netherlands, direct medical costs were
€221 million in 2005 [6]. In addition to the economic
burden, epilepsy imposes a substantial burden on the
patients themselves and their surroundings.
In the Netherlands, the point prevalence of epilepsy in
children and adolescents between 0-18 years is 4.77
boys, and 4.55 girls per 1,000 persons. The yearly inci-
dence of epilepsy in the Netherlands for children and
adolescents between 0-18 years is 0.58 per 1,000 boys
and 0.53 per 1,000 girls [7]. Although epilepsy is treata-
ble with anti-epileptic drugs in the majority of cases,
about 30% of patients suffer from drug-resistant epilepsy
[8]. Patients with uncontrolled epilepsy heavily depend
on informal care (family and friends) and on health care
professionals (neurologists, social workers, psychologists
etc.). Complications due to intractable epilepsy result in
frequent hospitalizations and many of these patients are
institutionalized. Patients with drug-resistant epilepsy
can potentially benefit from a ketogenic diet. The keto-
genic diet is a high-fat, low carbohydrate, normocaloric
diet that mimics the metabolic state of fasting. During a
prolonged fast, body energy requirements are met by
lipolysis and ß-oxidation of fatty acids rather than by
the breakdown of carbohydrates. The ketogenic diet
maintains an anabolic nutritional state in a metabolic
situation of fasting. Ketone bodies may produce an
anticonvulsant effect, presumably due to changes in cer-
ebral energy metabolism, in cell properties decreasing
excitability, in neurotransmitter function, in circulating
factors acting as neuromodulators and in the brain’s
extracellular milieu [9]. The ketogenic diet is generally
used for a period of up to 3 years. Seizure control bene-
fits are typically seen within 1-3 months of starting the
diet. The international study group reports that the diet
should be utilized for at least 3 1/2 months before
deciding to discontinue it [10]. The diet can be discon-
tinued earlier if seizures worsen beyond expectations or
if adverse effects cannot be corrected [11]. Medications
are tapered once the efficacy of the diet has been estab-
lished (usually within 3-6 months of diet initiation). The
diet is gradually tapered off by lowering its fat content
and increasing the carbohydrate and protein portion of
the diet until ketosis is eliminated. Tapering starts after
2 years of treatment, or earlier in case of intolerable side
effects, or in case of ineffectiveness.
Currently the scientific and clinical attention paid to
the role of the ketogenic diet is negligible. This means
that a ketogenic diet is often overlooked and underuti-
lized as a treatment option for children with intractable
epilepsy. An important reason for this is that relatively
few children and their parents can comply with the
stringent diet. Therefore, physicians are often reluctant
to initiate the diet. To offer more children the opportu-
nity to benefit from a ketogenic diet, we suggest that
the diet should be initiated and monitored under strictly
controlled circumstances in order to maximize
compliance.
The beneficial effect of a ketogenic diet has been stu-
died in multiple observational studies [12-20], reviews
[21-24] and in one randomized controlled trial [25].
Nevertheless, there is a lack of information about the
cost-effectiveness of the ketogenic diet, and conse-
quently health authorities have not been convinced of
its usefulness.
The aims of our prospective study are to provide more
evidence about the effectiveness and to investigate the
cost-effectiveness of treatment with a ketogenic diet KD
in comparison with usual care in children and adoles-
cents with drug-resistant epilepsy who are not eligible
for epilepsy surgery.
Methods/Design
The design and methods of a randomized controlled
trial (RCT) evaluating the (cost-) effectiveness of a keto-
genic diet in comparison with usual care in children and
adolescents with intractable epilepsy are described in
this paper. This study has been approved by the ethics
committee of the Academic Medical Centre Utrecht, the
Netherlands.
Research question
We defined the following research questions:
I) Effect evaluation
(1) What are the effects of the ketogenic diet in compar-
ison with usual care with respect to changes in seizure
frequency and seizure severity, side effects/complaints,
neurocognitive, socio-emotional functioning, and quality
of life?
II) Economic Evaluation
The economic evaluation will consist of a trial-based
and a model-based economic evaluation study.
IIa) Trial-based economic evaluation (1) From a social
perspective, is the ketogenic diet, in comparison with
usual care, preferable in terms of costs, effects and
utilities?
(2) What is the incremental cost-effectiveness ratio
(ICER) of the ketogenic diet in comparison with usual
care?
IIb) Model-based economic evaluation (1) In compari-
son with usual care, is the ketogenic diet preferable in
terms of costs and utilities during the remaining life
expectancy of the study population?
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T h ep r o p o s e ds t u d yi sap r o s p e c t i v eR C T .T h es u b j e c t s
will be randomized to either the ketogenic diet or to
usual care. The trial flow of the proposed subject enrol-
ment and randomization procedures are shown graphi-
cally in Figure 1. Embedded in this RCT will be a short-
term trial-based economic evaluation and a long-term
modelling study to investigate the long-term cost-effec-
tiveness and cost-utility of the ketogenic diet versus
usual care.
Participants
The patient population consists of children and adoles-
cents with drug-resistant epilepsy. Patients are eligible
to participate if they meet the following criteria: age
between 1 and 18 years old; having uncontrolled sei-
zures; not eligible for epilepsy surgery; no fatty acid oxi-
dation disorders and related diseases; no diabetes and
hyperinsulinism; no prolonged QT-time syndrome; no
hypercholesterolemia or hypertriglyceridemia; no severe
liver, kidney or pancreas diseases; no renal tubular
acidosis; no severe behavioral disorder; no malnutrition;
no treatment with topiramate or acetazolamide and no
positive family history or other risk factors for kidney
stones or acidosis.
Recruitment
Potential participants are screened for exclusion criteria
by their own attending paediatrician, neurologist or pae-
diatric neurologist. Children who are eligible to be trea-
ted with a ketogenic diet are subsequently referred to
the multidisciplinary ketogenic diet team at the epilepsy
centre Kempenhaeghe in the Netherlands. Eligible chil-
dren and their parents will first receive information by
telephone before getting an invitation for an information
visit. During the information visit eligibility is checked
by the multidisciplinary team. If they are interested, par-
ents, adolescents and/or children can find information
about the study on the website http://www.ketogeen-
menu.nl. Parents and potential candidates who are con-
sidering participating in the study will have at least one
week to decide, before signing informed consent.
Sample Size
A 50% reduction in seizure frequency is considered
clinically relevant and is defined as success. Assuming a
minimum detectable difference in success rate of 35%
between the ketogenic diet group and usual care, and
assuming that alpha = 5% and power = 80%, we need 22
children for each group. Taking dropouts into account,
we need 50 children in total. A drop-out is defined as a
child who drops out of the study before the first consul-
tation with the neurologist; this is scheduled 6 weeks
after initiating the KD or 6 weeks after randomization
to usual care.
Randomization and procedure
Randomization will occur halfway through the 4 week
baseline period. We will use a software package
(ALEA) to support the online patient registration and
randomization which will be based on the minimiza-
tion method. Patients will be stratified according to
age (1-6 years, 7-12 years, 13-18 years), having a PEG/
tube or not, and whether the child is living at a resi-
dential centre or attends the epilepsy centre as an out-
patient while she/he lives at home. In view of the
nature of the treatments, blinding of the patients and
researchers is not possible.
Intervention
Ketogenic diet
Patients assigned to the ketogenic diet group will be
hospitalized in the tertiarye p i l e p s yc e n t e rf o r1w e e k .
During this week the ketogenic diet is introduced by a
dietician. The anti-epileptic drugs the children and ado-
lescents use at the time of inclusion in the study will be
continued without changes during the study (except
when medically indicated). The initial calorie prescrip-
tion for the ketogenic diet is based on an average
between the pre-diet intake and the recommendations
for energy requirements, taking into account current
and previous weight and height, recommended caloric
requirements and levels of physical activity. The dieti-
cian will decide together with the parents whether the
classical diet or the medium-chain triglyceride (MCT)
diet is introduced. Sometimes the MCT diet is not pos-
sible and the classical ketogenic diet (3:1 or 4:1 ratio) is
advised. Children with a PEG/tube feed are also treated
with the ketogenic diet. The diet is then adjusted to a
fluid version. It is possible to decrease the titration of
Screening exclusion criteria by 
attending physician
Referral to KD team
Eligible subjects, N=50
4 weeks baseline period
Informed consent
Randomization T = 0
Ketogenic diet, N=25 Care as usual, N=25
Outcome measures
12 months follow-up
Outcome measures T = 3
FU = 4
Figure 1 Flowchart of the study.
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the initiation of the ketogenic diet.
Usual care
Patients randomized to usual care will continue to take
their anti-epileptic drugs and no changes will be made
to the anti-epileptic drugs treatment. Since a ketogenic
diet is a treatment of last resort, the children in the
usual care group will also receive a ketogenic diet after
a delay of four months. The controls will be treated and
monitored according to good clinical practice; however,
this is not part of our proposed study.
Timeline of the study
The timeline of the study is shown in Figure 2. Patients
in the intervention group will visit the multidisciplinary
team (nurse practitioner, dietician, paediatrician and
neurologist) at time points T0 (at baseline), T1 (during
admission), T2 (6 weeks after admission), T3 (4 months
after admission), FU1 (3 months follow-up), FU2 (6
months follow-up), FU3 (9 months follow-up), and FU4
(12 months follow-up). At T0, T3, and FU4 a neurocog-
nitive assessment will take place. An overview of mea-
surements per time point is shown in Table 1. Patients
in the intervention group will be asked to follow the
diet during the complete study period and during fol-
low-up, 16 months in total.
Patients in the usual care group will visit the multidis-
ciplinary team (nurse practitioner, paediatrician and
neurologist) at time points T0, T2, and T3 and will have
a neurocognitive assessment at T0 and T3. In case of
drop-out, a visit with the multidisciplinary team and a
neurocognitive assessment will take place.
I) Effect evaluation
Several instruments will be used to assess the effects of
the ketogenic diet on the primary outcome (seizure
frequency) and on secondary outcomes (seizure sever-
ity, side effects, neurocognitive assessment and quality
of life).
Primary outcome
Seizure frequency A seizure calendar is used to record
seizures. Types of seizures are described and labelled in
accordance with ILAE classification. The number and
type of seizures are recorded on the dates they occur.
Secondary outcome
Seizure severity The National Hospital Seizure severity
scale (NHS3) [26] is a structured interview in which the
clinician rater assigns a score to seizure severity based
on interference with patient function. Information is
gathered from the patient and witnesses, if available.
Eight questions are asked about: tonic-clonic move-
ments, falling, injury, incontinence, altered conscious-
ness, postictal impairment, and disruptive automatisms.
Side effects Subjective complaints are assessed using the
SIDAED (Side effects of Anti-Epileptic Drug), a list of
46 items with possible anti-epileptic drug-related com-
plaints. The items included in the SIDAED form 10
categories: general Central Nervous System (CNS),
behavior (increased irritability), depressive symptoms,
changes in cognitive function, motor problems and
coordination, visual complaints, headache, cosmetic and
dermatological complaints, gastrointestinal complaints,
and sexuality and menses. For each item the parents






























Figure 2 Timeline of the study. Note: T0 = baseline; T1 = Admission; T2 = 6 weeks after baseline period; T3 = 4 months after baseline period;
FU1 = 3 months follow-up; FU2 = 6 months follow-up; FU3 = 9 months follow-up; FU12 = 12 months follow-up.
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In addition, the duration of the complaints is scored (for
a few weeks, for months or for a half year or longer).
Neurocognitive assessment Peabody Picture Vocabu-
lary test
The Peabody Picture Vocabulary test (PPVT-III-NL:
Dutch version) is an individually administered measure
of receptive vocabulary [27]. The test can be adminis-
tered beginning at the age of 2 1/2 years. The child lis-
tens to the examiner’s stimulus word and must choose
the picture that best describes the word from a 4-pic-
ture multiple choice array. The score on this test can be
interpreted as an achievement test of the child’s vocabu-
lary that does not require a verbal response and as a
screening measure of verbal ability. There is supportive
data for the validity of the PPVT-III as a measure for
global cognitive intelligence.
Beery Developmental Visual-Motor Integration test
The Beery Developmental test of Visual-Motor Inte-
gration (Beery-VMI) is a widely used assessment of psy-
chomotor development. It measures problems with
visual perception, motor coordination, and visual motor
integration. The 30-item test can be administered from
the age of 2 years. The Beery VMI was standardized on
a national US sample of 1,737 individuals age 2 to 18
years (2010) and 1,021 adults ages 19-100 (2006), and
has proven reliability and validity [28].
Fepsy computerized test
T h eF e p s yi san e u r o c o g n i t i v ec o m p u t e r i z e dt e s tb a t -
tery consisting of different subtests. For this study we use
the simple auditory and visual reaction times, in which
the stimulus exposure endures until a push-button
(space-bar) response is given [29]. Simple reaction tests
give information on alertness functions and on the speed
at which the information processing system is activated.
We also use the binary choice reaction task in which a
combination of accuracy and speed of responses are mea-
sured. This test measures the speed of central informa-
tion processing. Finally, we use the finger tapping task in
which motor activation and fluency is measured. In gen-
eral, these tests can be administered from the age of 6.
Kaufman Assessment Battery
The Kaufman Assessment Battery for Children II (K-
ABC II) is used to investigate the level of information
processing capacities of children beginning at the age of
2 1/2 years [30]. Two subtests will be administered: (1)
Number recall, which is a measure of sequential proces-
sing and short term memory. The examiner says a series
of numbers and the child repeats them. Digit span for-
ward is considered a measure of efficiency of attention
Table 1 Overview of measurements per time point
Measurement T0 T1* T2 T3 FU1* FU2* FU3* FU4*
Demographic characteristics x
Clinical measurement x x x x xxxx
National Hospital Seizure severity scale x x x x xxxx
Side effects of Anti-Epileptic Drug x x x x xxxx
Credibility And Expectancy Questionnaire x
Peabody Picture Vocabulary test x x x
Beery Developmental Visual-Motor Integration test x x x
Fepsy computerized test x x x
Kaufman Assessment Battery x x x
Actigraphy x x x
SEV Questionnaire x x x
SDQ Questionnaire x x x
POMS Questionnaire x x x
The Personal Adjustment and Role Skills Scale x x x
The Hague Restrictions in Childhood Epilepsy Scales x x x
EuroQol x x x
TAPQOL or TACQOL x x x
Blood x x x xxxx
Urine x x x xxxx
Keton bodies measurement x x x x xxxx
E C G x x xxxx
T0 = baseline; T1 = Admission; T2 = 6 weeks after baseline period; T3 = 4 months after baseline period; FU1 = 3 months follow-up; FU2 = 6 months follow-up;
FU3 = 9 months follow-up; FU12 = 12 months follow-up; *= intervention group only.
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thinking, which is a measure of nonverbal reasoning
skills. The child looks at pictures and determines the
one that does not belong.
Actigraphy
During the administration of the PPVT-III and the K-
ABCII test, an actigraphic device (Actiwatch
® model
AW4: Cambridge Neurotechnology Ltd., United King-
dom) will be used to assess motor activity as a measure
of alertness. As some of the children in the design are
not testable with the described cognitive tests we
decided to use an assessment of motor activity in a stan-
dardized situation. A wrist watch will be used that trans-
lates activity into movement of the watch hand.
Registration takes place in a standardized way during
the first 10 minutes of the Peabody Picture Vocabulary
test and the first 5 minutes of the K-ABC-II test. When
patients are not eligible to perform the neurocognitive
assessment, the wrist watch will be used for 15 minutes
during the visit at the nurse practitioner’s office while
watching a DVD with songs and pictures.
SEV Questionnaire
The SEV questionnaire (Sociaal Emotionele Vragen-
lijst: Social Emotional Questionnaire) is a DSM-IV
oriented questionnaire which is used to assess four
domains of behavioral and social emotional dysfunction.
These domains are: Attention Deficit Hyperactivity Dis-
orders, Oppositional Defiant behavior and Conduct Dis-
orders, Anxiety and Depression, and Autism spectrum
disorders. The questionnaire consists of 72 items
describing problem behavior [31].
SDQ Questionnaire
The Strengths and Difficulties Questionnaire (SDQ) is
a brief behavioral screening questionnaire that provides
balanced coverage of children and young people’s beha-
viors, emotions, and relationships [32]. The SDQ is
applicable to children beginning at the age of 4 and asks
about 25 attributes that are divided into five relevant
dimensions: namely conduct problems, emotional symp-
toms, hyperactivity, peer relationships, and pro-social
behavior.
POMS Questionnaire
The Profile of Mood States (POMS) has been devel-
oped to identify and assess seven transient, fluctuating
affective mood states: Tension-Anxiety, Depression-
Dejection, Anger-Hostility, Vigour-Activity, Fatigue-
Inertia, Friendliness, and Confusion-Bewilderment [33].
The questionnaire contains 65 items. All items describe
an emotional state which can be rated on a 5-point
scale ranging from “not at all” to “extremely”.
The Personal Adjustment and Role Skills
Scale (PARS)
The Personal Adjustment and Role Skills Scale, 3rd
edition (PARS-III) was specifically developed to measure
psychosocial adjustment in children with chronic physi-
cal illness [34]. This instrument is a brief parent-com-
pleted index of youth psychosocial adjustment. The
instrument yields six factor-derived psychosocial sub-
scales: namely peer relations, dependency, hostility, pro-
ductivity, anxiety/depression, and withdrawal. The
PARS-III is a reliable and valid index of youth psychoso-
cial adjustment and can be used for both clinical screen-
ing and research purposes [35].
The Hague Restrictions in Childhood Epilepsy
Scales (HARCES)
The HARCES is a questionnaire consisting of 11 items
used to assess impairments in daily functioning that are
related to epilepsy, e.g. how much influence does the
epilepsy have on your child’s freedom of functioning in
the house? Items are answered on a 4-point scale ran-
ging from “no impairment” to “very much impairment”
[36].
Credibility And Expectancy questionnaire (CEQ) The
Credibility and Expectancy Questionnaire (CEQ) [37] is
a multidimensional self-reported instrument of 6 items,
rated on a 9- or 10-point Likert-scale, meant to measure
the expectancy and credibility a person has about the
therapy he or she will receive. Its sound psychometric
properties have been proven. We will measure the cred-
ibility and expectancy for the treatment of both the chil-
dren and their parents.
Generic quality of life EuroQol
Living with uncontrolled seizures has a negative
impact on the quality of life of the child and his/her
parents. Therefore, we will measure generic quality of
life of both the children and their parents. For this pur-
pose we will use the EuroQol instrument for children of
12 years and older developed by the EuroQol group
[38]. For younger children, we will use a version of the
EuroQol developed for children (EuroQol-Youth) or
proxies (Wille, 2010). In accordance with the regular
EuroQol, the EuroQol-Youth is comprised of the follow-
ing 5 dimensions: mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. Each dimension
has 3 levels: no problems, some problems and severe
problems, thus defining 243 (3
5) possible health states.
‘Unconscious’ and ‘dead’ have been added to these
states, resulting in a total of 245 states. Furthermore,
the EQ-5 D consists of a visual analogue scale (VAS)
ranging from zero (worst imaginable health state) to 100
(best imaginable health state).
TAPQOL or TACQOL
QoL will also be assessed using the TAPQOL (TNO-
AZL Preschool Children’s Quality of Life) for children
aged between 1-5 years [39] and the TACQOL (TNO-
AZL Children’s Quality of life) for children aged
between 6-16 years [40]. There are 12 dimensions in the
TAPQOL: lungs, stomach, skin, sleep, appetite,
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social behavior, motor functioning and communication.
All dimensions are scored on a scale from 0-100. The
TACQOL is comprised of 7 dimensions: bodily com-
plaints, independence, motor functioning, cognition,
social functioning, positive and negative emotions. The
scores of the first 5 dimensions vary from 0-32 and the
scores of the last two dimensions from 0-16.
II) Economic evaluation
The economic evaluation will be performed from the
societal perspective, which implies that all relevant costs
and effects will be taken into account. The economic
evaluation compares costs and effects of the ketogenic
diet in comparison with usual care. A Cost-Effectiveness
Analysis (CEA) and a Cost-Utility Analysis (CUA) will
be performed. Outcomes of interest for the CEA and
the CUA will be the reduction of seizures and improve-
ment in the Quality Adjusted Life Years (QALYs)
respectively. The QALY is a measure of disease burden,
including both the quality (utilities) and the quantity of
life lived. Total societal costs will be calculated based on
the Dutch guidelines for cost calculations in health care.
We distinguish four cost categories: intervention costs,
health care sector costs, costs for the patient and family,
and productivity costs. For this study, three instruments
are used to measure the costs and utilities.
Prospective cost diary
The diary is used to identify all relevant cost aspects
with respect to health care sector costs and patient and
family costs [41]. Each diary covers a period of four
weeks and will be filled out during the 4 week baseline
period and during the 4 month study period. The inter-
vention group will also fill out the diary during the 12
months of follow-up. Total costs will be estimated using
a bottom-up approach, where information on each ele-
ment of service used will be multiplied by an appropri-
ate standardized unit cost and be summed to provide an
overall total cost. For the cost valuation, standardized
cost prices from the Dutch manual for cost analysis in
health care research will be used [42].
Productivity losses
A retrospective questionnaire and the patient modules
of the PROductivity and DISease Questionnaire (PRO-
DISQ) [43] will be used to measure production losses of
the patient’s parents. Productivity costs will be calcu-
lated by means of the friction cost method, based on a
mean added value of the Dutch working population.
This method takes into account production losses con-
fined to the period needed to replace a sick employee.
Utilities (EQ-5D)
Both generic quality of life, as well as utilities, will be
derived by means of the EuroQol, as mentioned before.
Utility values will be calculated for all health states of
the EuroQol, using preferences from the UK general
population value set which provides an algorithm as a
series of decrements from 1, the value of full health.
Values of the UK population for the scoring function of
the health states described by the EQ-5D were measured
with the Time Trade Off (TTO) technique (see Tor-
rance, 1976) on a random sample of approximately 3000
members of the adult population of the UK [44]. The
utility values derived from the Dolan algorithm will be
used to compute Quality Adjusted Life Years (QALYs).
However, to overcome the tariff’s differences between
countries, the Dutch tariff is also used to calculate utili-
ties in the sensitivity analysis. Lamers [45], calculated by
means of the TTO method a Dutch scoring function for
the health states described by the EQ-5D, based on a
Dutch population sample of 300 people.
Analyses
I) Effect evaluation
Our primary (base-case) analyses will be performed
according to the intention-to-treat principle, including
data from all participants regardless of whether they
received the intervention or not. For the analyses we
will use SPSS statistical software. Respondents for whom
at least 75% of the data per measurement instrument
are available will be included in the analysis. Missing
data on an item level will be handled using SPSS miss-
ing value regression analysis. Completely missing mea-
surements will be handled using multiple imputation.
Between-group differences in proportions (dichotomous
variables) will be tested using the Chi-square test and
between-group differences in means (continuous vari-
ables) will be tested using Student’s t-test for indepen-
dent samples. In addition, a multivariate regression
analysis will be performed with the covariates of sex,
age, severity of disease, duration of disease etc. The
accuracy of the findings will be expressed in terms of
95% confidence intervals.
IIa) Trial-based economic evaluation
A baseline analysis will be performed to examine the
comparability of groups at baseline for both costs and
outcomes. If necessary, methods will be applied to con-
trol for differences in baseline [46]. A Kolmogorov-
Smirnov test will be performed to investigate whether
data are distributed normally. Despite the usual skew-
ness in the distribution of costs, the arithmetic means
will generally be considered the most appropriate mea-
sures for describing cost data [47,48]. Therefore, arith-
metic means (and standard deviations) will be
presented. In case the cost data are skewed, non-para-
metric bootstrapping will be used to test for statistical
differences in costs between the intervention and usual
care. The bootstrap replications will be used to calculate
95% confidence intervals around the costs (95% CI),
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are distributed normally, t-tests will be used. The incre-
mental cost effectiveness ratio (ICER) will be determined
on the basis of the incremental costs and effects of the
ketogenic diet in comparison with a waiting-list group.
The cost-effectiveness ratio will be stated in terms of
costs per outcome rate (decrease in seizure frequency
and severity), and the cost-utility ratio will focus on the
net cost per utility gained.
The robustness of the ICER will be checked by non-
parametric bootstrapping. Bootstrap simulations will
also be conducted in order to quantify the uncertainty
around the ICER, yielding information about the joint
distribution of cost and effect differences. The boot-
strapped cost-effectiveness ratios will be plotted subse-
quently in a cost effectiveness plane. The choice of
treatment depends on the maximum amount of money
that society is prepared to pay for a gain in effectiveness,
which is called the ceiling ratio. Therefore, the boot-
strapped ICERs will also be depicted in a cost-effective-
ness acceptability curve showing the probability that the
ketogenic diet is cost-effective using a range of ceiling
ratios. In addition, to demonstrate the robustness of our
base-case findings, multi-way sensitivity analyses will be
performed [49].
IIb) Model-based economic evaluation
The time horizon of the Cost Utility Analysis (CUA)
will be extrapolated towards the remaining life expec-
t a n c yo ft h es t u d yp o p u l a t i o n .T h eC U Ai so fm a j o r
importance since the impact of a ketogenic diet on sei-
zure reduction, costs, and QoL reaches beyond the 4-
month study period of the clinical study. A Markov
Monte Carlo decision analytic model will be developed
to calculate lifetime incremental costs and incremental
QALYs of treatment with a ketogenic diet in compari-
son with treatment with anti-epileptic drugs only. Mar-
kov models assume that a patient is always in one of a
finite number of health states. All events are represented
as transitions from one state to another. A first-order
Monte Carlo evaluation of a Markov model determines
t h ep r o g n o s e so fal a r g en u m b er of individual patients.
The time horizon of the analysis is divided into cycles.
Each patient begins in an initial state. During each cycle,
the patient may make a transition from one state to
another according to the laws of chance, as dictated by
the transition probabilities. After the first patient has
completed the simulation, another patient begins in the
initial state and a new simulation is performed. This
process is repeated a very large number of times, and
each simulation generates a quality adjusted survival
time and costs. Monte Carlo analysis, as opposed to a
Markov cohort model without memory, offers the possi-
bility to flag subjects in order to track their characteris-
tics and disease histories; this is a very flexible approach
to modelling variability within a population. The model
will combine the results of the clinical study and data
from the medical literature. In the modelling study we
will also perform probabilistic sensitivity analysis to test
parameter uncertainty and to construct cost-effective-
ness acceptability curves. Future costs and effects will be
discounted according to the Dutch guidelines for cost
calculations in health care [42].
Discussion
Our design is aimed at assessing the effectiveness and
cost-effectiveness of a ketogenic diet among children
and adolescents with intractable epilepsy. It is a pro-
spective RCT comparing the ketogenic diet with usual
care.
The ketogenic diet can be a treatment of last resort
for patients with intractable epilepsy. This alternative
therapy is used only in the minority of children who
could potentially benefit from it. In order to optimize
therapy for children with uncontrolled seizures, the
ketogenic diet should be prescribed for more children
with intractable epilepsy.
Limitations and complications
Compliance with a ketogenic diet is difficult due to its
restrictive nature. Unfortunately, non-compliance limits
the intended effect and increases the costs to society,
resulting in a less favorable cost-effectiveness ratio. In
order to overcome this problem, the children and ado-
lescents with uncontrolled epilepsy who are on the keto-
genic diet will be monitored according to a strict
standardized protocol. Therefore it is likely that the effi-
ciency of patient care will improve. However, a formal
assessment of the diet’s cost-effectiveness has not yet
been performed and is the focus of the present proposal.
Conclusion
Growing up with seizures affects the child’s personality
and cognitive development and interferes with many
aspects of everyday life, including learning at school, lei-
sure and occupational activities. Epilepsy has been
shown to have a high impact on quality of life when
children have intractable seizures and additional
disabilities.
This study will provide information about the cost-
effectiveness of the ketogenic diet, its effects on clinical
outcomes, on neurocognitive functioning and on quality
of life. Our study is the first study assessing the cost-
effectiveness of a ketogenic diet.
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